TITLE

Tigermed Cooperates with Simcere in Drugs R&D

PUB. DATE
December 2009
SOURCE
China Chemical Reporter;12/26/2009, Vol. 20 Issue 36, p13
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article announces the partnership agreement signed by the leading Contract Research Organization (CRO) Tigermed Consulting Co. Ltd. and Jiangsu Simcere Pharmaceutical Group in China. It states that the agreement will see the two companies to collaborate in many aspects pertaining to medicine research and development. A brief overview of the background and services of Tigermed is presented.
ACCESSION #
47276049

 

Related Articles

  • Other News To Note.  // BioWorld Today;11/4/2010, Vol. 21 Issue 214, p4 

    This section offers news briefs related to the pharmaceutical industry as of November 4, 2010. Adventrx Pharmaceuticals Inc. plans to file for a regulatory approval to the U.S. Food and Drug Administration for ANX-530 (vinorelbine injectable emulsion) or Exelbine. Biogen Idec Inc. will implement...

  • Indian Pharma Sector: Evolving to Innovation. Iakdawala, A. D. // Pharmaceutical Technology;Apr2007, Vol. 31 Issue 4, p88 

    The article focuses on the paradigm shift from reverse drug engineering to new drug discovery in the pharmaceutical sector in India. According to the author, the government's implementation of product patent law has forced the pharmaceutical companies to invest in the discovery of new drugs. To...

  • MAKING KNOWLEDGE AND MAKING DRUGS? EXPERIMENTING WITH UNIVERSITY INNOVATION CAPACITY. Vertinsky, Liza // Emory Law Journal;2013, Vol. 62 Issue 4, p741 

    No abstract available.

  • Fail Like the Pros. Lowe, Derek B. // Contract Pharma;Sep2012, Vol. 14 Issue 7, p30 

    The article reports on the factors that pharmaceutical companies must consider to achieve a successful drug discovery project. It notes the need for companies to set exact numbers of drug development projects each year to avoid distraction. Moreover, it mentions to establish rules, procedures,...

  • THE BIG IDEA: PRIZES TO STIMULATE R&D FOR NEW MEDICINES. Love, James; Hubbard, Tim // Chicago-Kent Law Review;2007, Vol. 82 Issue 3, p1519 

    The authors feature "The Big Idea: Prizes to Stimulate R&D for New Medicines," a paper presented as the Ruby Hutchison Memorial Address on November 14, 2006, in Sidney, New South Wales. The paper provides background on prizes and their application to medical research. It also discusses the...

  • Drugs development is cheaper than widely claimed, experts say. Pflumm, Michelle // Nature Medicine;Apr2011, Vol. 17 Issue 4, p395 

    The article focuses on the study regarding the cost of research and development of new drugs, which shows that drug development cost is cheaper than widely claimed by the pharmaceutical industry to justify the high prices charged for prescription drugs. It says that companies spend about 60...

  • Can Open-Source Drug R&D Repower Pharmaceutical Innovation? Munos, B. // Clinical Pharmacology & Therapeutics;May2010, Vol. 87 Issue 5, p534 

    Open-source R&D initiatives are multiplying across biomedical research. Some of them—such as public–private partnerships—have achieved notable success in bringing new drugs to market economically, whereas others reflect the pharmaceutical industry’s efforts to retool...

  • Life sciences infused in Michigan. Mirasol, Feuza // Chemical Market Reporter;12/19/2005, Vol. 268 Issue 20, p24 

    This article reports that the pharmaceutical company Pfizer Inc.'s continued presence in the Kalamazoo region, Michigan, accounted for a good majority of the start-up firms' current business. The company operates three facilities in the area including a 2,100-acre farm for animal health...

  • Big Pharma, Bad Medicine: How corporate dollars corrupt research and education. Angell, Marcia // Boston Review;May/Jun2010, Vol. 35 Issue 3, p7 

    This article presents issues on how drug companies can corrupt medical research and education. It notes that drug companies do research by contracting some research organizations, who are organizing doctors in private practice, to enroll their patients in clinical trials to increase their...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics